Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | Tocilizumab for AA amyloidosis

Luis Quintana • 4 Sep 2020
ISA 2020
Amyloidosis Rare Diseases Antibodies Tocilizumab

Anti-interleukin-6 receptor, tocilizumab, has demonstrated improvements in the clinical symptoms of patients with AA amyloidosis, being associated with regression of amyloid deposition. Luis Quintana, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain discusses the use of this agent for AA amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Luis Quintana

1:04
AA amyloidosis management
Luis Quintana • 10 Sep 2020
1:53
Renal complications post-transplantation
Luis Quintana • 3 Sep 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals